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SUMMARY 
This Practice Point commentary discusses the study by Yao et al. in which primary 
androgen deprivation therapy (PADT) was compared with conservative treatment in 
elderly men with localized prostate cancer. Overall, PADT was associated with worse 
cancer-specific survival; however, in the subgroup of patients with poorly differentiated 
cancer, PADT was associated with improved cancer-specific survival compared with 
conservative management. Whereas the authors defined conservative treatment as no 
definitive treatment during the 180 days after diagnosis, many of these patients would 
have subsequently received definite treatments, including surgery or radiation therapy. 
The results, therefore, do not necessarily demonstrate inferiority of PADT to 
conservative treatment. Accurate evaluation of the efficacy of PADT is confounded by a 
number of factors, such as the type of ADT used. Efforts should be made to reduce the 
adverse effects of ADT, because a high proportion of patients actively choose to receive 
PADT. 
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 COMMENTARY 
In an article published in The Journal of the American Medical Association, Yao et al.1 
have investigated prostate-cancer-specific and overall survival in elderly men (greater 
than or equal to 66 years) with localized prostate cancer, comparing patients treated 
with primary androgen deprivation therapy (PADT; started within 180 days after 
diagnosis, with no surgery or radiation therapy given during this period) with those who 
received conservative treatment (no definitive treatment during this period). Statistical 
analysis was performed using instrumental variable analysis to control for both 
measured and unmeasured confounding variables. Of a total of 19,271 patients with 
localized prostate cancer, 41% received PADT and the remainder was managed 
conservatively. During the follow-up period, 1,560 patients died of prostate cancer and 
11,045 deaths from all causes were reported. PADT was associated with lower 
prostate-cancer-specific survival and no change in overall survival compared with 
conservative management. For the subgroup of patients with poorly differentiated 
cancer, PADT was associated with improved prostate-cancer-specific survival, and a 
borderline improvement in overall survival. On the basis of the above results, the 
authors concluded that PADT was not associated with improved survival among the 
majority of elderly men with localized prostate cancer in comparison with conservative 
management. 
 The role of PADT in localized prostate cancer has not been well defined. Data 
on the current treatment of prostate cancer in Japan show that PADT is chosen for 
localized prostate cancer in an extremely high proportion of cases2. The US Cancer of 
the Prostate Strategic Urologic Research Endeavour (CaPSURE) has also shown 
increasing use of PADT for localized prostate cancer in recent years. Concern is 
growing, therefore, that PADT is being applied without clear evidence to support its use, 
because there have been many papers which showed ADT-associated morbidities. 
 Although the authors emphasized the inferiority of PADT in the treatment of 
localized prostate cancer, this conclusion has some limitations. The authors defined the 
PADT group as patients who received PADT during the 180 days after diagnosis, and 
the conservative treatment group as those who did not receive surgery, radiation therapy, 
or ADT during this period. A large number of patients in the latter group, however, 
might have received definitive treatments, including radical prostatectomy or radiation 
therapy, after 180 days. Indeed, one study has shown that approximately half of patients 
managed by watchful waiting received such treatments within 5 years.3 The results 
indicating that the PADT group had lower prostate-cancer-specific survival and similar 
overall survival compared with the conservative management group do not, therefore, 
necessarily demonstrate inferiority of PADT to conservative treatment, although it is 
unknown what percentage of the PADT group received definitive treatment after 180 
days 
 The authors explained the poor cancer-specific survival of the subgroup of 
patients with moderately differentiated cancer who received PADT by suggesting that in 
these patients PADT might result in overgrowth of more-rapidly growing malignant 
clones. Unfortunately, such a hypothesis is unlikely to be tested in the clinical setting. 
Kitagawa et al.4 investigated the clinical and pathological effects of ADT using tissue 
specimens from patients treated with radical prostatectomy after neoadjuvant ADT. 
More than 40% of specimens showed complete histological cure (no cancer cells or 
complete apoptosis) or near cure (more than half of whole cancer cells apoptotic). In 
addition, the recurrence-free survival for patients with histologically cured specimens 
was 100%. These results support the suggestion of long-term control or cure by PADT 
alone in some cases of localized prostate cancer.5,6 The present study should stress that 
the PADT-treated subgroup with poorly differentiated cancer demonstrated improved 
prostate-cancer-specific survival. 
 Currently, little high-quality evidence regarding comparative efficacy and 
adverse effects is available to guide patients selecting treatments for localized prostate 
cancer.7 Accurate evaluation of the efficacy of PADT is especially difficult, because 
many factors, such as type of ADT (i.e. combined androgen blockade, castration 
monotherapy or antiandrogen therapy), duration of ADT, and ethnicity, affect the 
outcome of therapy. Most patients, therefore, select a particular treatment on the basis of 
their own feelings. Many factors which contain not only efficacy and adverse effects, 
but also an anxiety or psychological burden about their treatments may be involved in 
their decision-makings. . Although clinical practice guidelines and most urologists do 
not recommend PADT as treatment for localized prostate cancer, many patients actually 
select PADT. We should consider why so many patients select PADT even after accurate, 
comprehensive explanations to aid in treatment decision-making by their attending 
physicians. Medical treatment, such as PADT, is probably more acceptable to some 
patients than more-invasive treatment, such as surgery  In addition,  their attending 
physicians themselves acquiesce to patients’ wishes, perhaps because these physicians 
have previously seen successful outcomes with PADT.. The Prostate Cancer Outcomes 
Study8 of adverse effects of treatment and patient satisfaction yielded interesting results; 
satisfaction was higher in men who received early intervention, including PADT, than in 
those who received watchful waiting. In addition, the study showed that most patients 
who have received a particular treatment would make the same treatment selection 
again, no matter what treatment is the best. Therefore, what is important is how 
adequately the physicians are able to monitor and diminish potential consequences 
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 Practice point 
Although this study found worse long-term cancer-specific survival with primary 
androgen deprivation therapy (PADT) than with conservative treatment, the results do 
not necessarily indicate inferiority of PADT because of the confounding effect of 
subsequent definitive treatment. Ｗhat is important is how adequately the physicians 
are able to monitor and diminish adverse effects of each treatment. 
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